Рынок фиксированных комбинаций амло

Рынок фиксированных комбинаций амлодипина с аторвастатином продолжает падать, особенно в деньгах (приблизительно -8.1%). Причиной этому стал значительный рост цен на препараты этой группы в апреле 2014г. Розничная цена на препарат Дуплекор остается самой высокой среди фиксированных комбинаций. Продажи препарата Дуплекор в конце первого полугодия упали почти в 2 раза и в упаковках, и в деньгах. По-прежнему отсутствует самая востребованная форма 20/5.
Прямыми конкурентами остаются Кадуэт(Pfizer) и Амлостат(Kusumpharm). Промоции этих препаратов стала более активная. Активно принимают участие во всех конференциях, круглых столах. У компания «Pfizer» стартовала программа лояльности для врачей и пациентов.

Результаты (английский) 1:

The market of fixed combinations of amlodipine with atorvastatin is appropriate continues to fall, especially in the money (approximately-8.1%), the reason for this was the significant increase in prices for products of this group in April 2014. The retail price of the drug Duplekor is the highest among the fixed combinations. Sale of Duplekor at the end of the first half fell by nearly 2 times and in packages, and in money. There is still the most popular form of 20/5.
direct competitors are Kaduèt (Pfizer) and Amlostat (Kusumpharm). Promotion of these drugs has become more active. Actively take part in all the conferences, round tables. The company "Pfizer" started a loyalty program for physicians and patients.

Результаты (английский) 2:

Market fixed combinations of amlodipine with atorvastatin continued to fall, especially in the money (about -8.1%). The reason for this was a significant increase in prices for drugs in this group in April 2014. Retail price for the drug Duplekor remains the highest among fixed combinations. Sales of Duplekor late in the first half of the year fell by almost a factor of 2 and in packages and money. Still missing the most requested form 20/5.
Direct competitors are Kaduet (Pfizer) and Amlostat (Kusumpharm). Promotion of these drugs has become more active. Actively participate in all conferences, round tables. The company «Pfizer» launched a loyalty program for physicians and patients.

Результаты (английский) 3:

The market fixed combinations with амлодипина аторвастатином continues to drop, especially in money (approximately -8.1 % ). The reason this has become a significant rise in prices for drugs this group in April 2014.Retail price for the medication Дуплекор remains the highest fixed combinations. Sales Дуплекор at the end of the first half fell almost in 2 times and in packages, and the money.There continues to be no the most VCP form 20/5.
direct competitors remain Кадуэт(Pfizer) and Амлостат(Kusumphаrm). Publicâ these drugs has become more active. Actively participate in all conferences,Round tables. The company "Pfizer" loyalty program for doctors and patients.